头孢哌酮-舒巴坦对老年患者下呼吸道感染的疗效与安全性评价

目的：评价头孢哌酮-舒巴坦用于治疗老年患者下呼吸道感染的临床疗效及其安全性。方法：选取下呼吸道感染的老年患者 100 例，根据分组原则将其分为 A 组与 B 组，其中 A 组患者给予头孢哌酮-舒巴坦治疗，B 组给予头孢他啶治疗，并对比 A、B 两组患者经治疗后细菌清除率及总有效率等指标。结果：经治疗后对各种细菌分离及清除数量比较，其结果显示治疗后 A 组清除率（92.31%）高于 B 组（57.69%）（P＜0.05）；A 组总有效率（100%）显著高于 B 组（88.0%）（P＜0.05）。结论：临床使用头孢哌酮-舒巴坦治疗老年患者下呼吸道感染的疗效高且不易产生耐药性。

Clinical Efficacy and Safety Evaluation of Cefoperazone-sulbactam in Treatment of Elderly Patients with Lower Respiratory Tract Infection

Objective： To evaluate the clinical efficacy and safety evaluation of cefoperazone-sulbactam in elderly patients with lower respiratory tract infection. Methods： One hundred cases of elderly patients with lower respiratory tract infection, based on the grouping principle were divided into group A and group B. Among them, the A group was treated with cefoperazone-sulbactam, group B was treated with ceftazidime treatment. After two groups are treated, bacterial clearance rate and total effective rate were comparad. Results： The results show that after treatment, bacteria isolation and removal group A clearance （92.31%） was higher than that of group B （57.69%）（P〈0.05）; therapeutic effect comparison showed that A after treatment total effective rate 100%, significantly higher than that of B 88% （P〈0.05）. Conclusion： The curative effect of cefoperazone-sulbactam in treatment of elderly patients with lower respiratory infection is significant and it was not easy to produce resistance.